<SEC-DOCUMENT>0001193125-25-314364.txt : 20251210
<SEC-HEADER>0001193125-25-314364.hdr.sgml : 20251210
<ACCEPTANCE-DATETIME>20251210165458
ACCESSION NUMBER:		0001193125-25-314364
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20251210
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251210
DATE AS OF CHANGE:		20251210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aardvark Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001774857
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				821606367
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42513
		FILM NUMBER:		251562564

	BUSINESS ADDRESS:	
		STREET 1:		4370 LA JOLLA VILLAGE DRIVE
		STREET 2:		SUITE 1050
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122
		BUSINESS PHONE:		(858) 225-7696

	MAIL ADDRESS:	
		STREET 1:		4370 LA JOLLA VILLAGE DRIVE
		STREET 2:		SUITE 1050
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ck0001774857-20251210.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-12-10T16:45:32.6551+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ck0001774857="http://aardvarktherapeutics.com/20251210" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_c60d0c38-5a87-4f49-b0a8-c37fa816e7d8" name="dei:AmendmentFlag" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856">false</ix:nonNumeric><ix:nonNumeric id="F_646edefe-1104-4a5c-9091-78be623abe93" name="dei:EntityCentralIndexKey" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856">0001774857</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="ck0001774857-20251210.xsd"/></ix:references><ix:resources><xbrli:context id="C_cca47cb1-b879-4739-a929-d7c7ef607856"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001774857</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-12-10</xbrli:startDate><xbrli:endDate>2025-12-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_19ff11d6-457e-4ac9-9375-f62ab0f89ef7" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></h2><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_e2f66d71-ca03-4d10-be54-be3207e2ce04" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 10, 2025</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b2f054e9-c53b-4ec3-9598-672877d13569" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Aardvark Therapeutics, Inc.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:18%;box-sizing:content-box;"/>
     <td style="width:41%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3aa45972-9a81-41e6-9e91-76fd704a1b09" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_29ba7234-a544-432e-8988-5dd677cf5249" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-42513</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3d72b4fd-b069-4aaa-a435-e57c4096a1e1" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">82-1606367</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_da157c2c-0375-4f21-be55-bc549ab27060" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4370 La Jolla Village Drive, Suite 1050</span></ix:nonNumeric></span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f7ed738e-0bfb-49c1-81d6-8476631ba090" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">San Diego</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_241a2319-f124-4b25-b0e1-45f3e487fe52" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5f1fdfb8-3292-4a86-bb6b-a021a7b60246" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">92122</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_da54936d-78d7-4288-b4d7-fc6aa62fd96b" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(858)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_398db6e3-33c7-4b55-b189-b8245004f9ae" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">225-7696</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_934325b3-3685-4609-9d8f-ebd29e122aa8" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856" name="dei:EntityInformationFormerLegalOrRegisteredName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">N/A</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:3pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9261a67-4d94-46b7-900d-6c5bb042a1ad" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0fa20ab3-ef9d-4de1-9ba8-d89e891dd52e" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c61dd3b3-25eb-41e8-a82d-eed69c9fef31" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_02d09e01-d257-42d0-8ea7-4c304ed46c7d" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:45%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Title of each class</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f67bc350-f156-4c3c-a415-351e45c2d347" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, par value $0.00001 per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_49040936-7831-4e47-bc4b-d1b40ae52d87" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">AARD</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_88e22f2b-ae80-4eba-82f6-dcf73698a15f" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_388285ae-3dfd-4e0f-a91a-f9127a32a676" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;"><ix:nonNumeric id="F_53859792-34b8-483b-833d-0210a7ac3b17" contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8.01 Other Events.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 10, 2025, Aardvark Therapeutics, Inc. (the &#8220;Company&#8221;) issued a press release announcing that the first patient has been dosed in Australia in the Company's Phase 3 HERO pivotal clinical trial assessing ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi syndrome. Additionally, regulatory clearance for enrollment by clinical trial sites in Canada and the United Kingdom participating in the HERO trial has also been received. At this time, the Company anticipates that it will not need to activate previously planned sites in the EU to fully enroll the HERO trial and meet its anticipated timeline for topline data readout in the third quarter of 2026.  The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Exhibits.</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:9.08%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:89.92%;box-sizing:content-box;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit<br/>No.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="ck0001774857-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release, dated December 10, 2025.</span></a></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span>&#160;</h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:44%;box-sizing:content-box;"/>
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:46%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">AARDVARK THERAPEUTICS, INC.</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 10, 2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Tien-Li Lee, M.D.</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tien-Li Lee, M.D.<br/>Chief Executive Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ck0001774857-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2025-12-10T16:45:32.6524+00:00 --><!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">                                                                                                                                                                       Exhibit 99.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><img src="img213560662_0.jpg" alt="img213560662_0.jpg" style="width:193px;height:76px;"></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical trial sites in Canada and the United Kingdom have received regulatory clearance to enroll</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">All patients who have completed HERO trial to date have successfully enrolled and remain in the Open Label Extension trial</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">SAN DIEGO &#x2013; December 10, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that the first patient has been dosed in Australia in its Phase 3 HERO pivotal clinical trial assessing ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi syndrome (PWS). Additionally, regulatory clearance for enrollment by clinical trial sites in Canada and the United Kingdom has also been received. Based on strong enrollment in the US and continued progress in advancing the clinical trial internationally, the clinical trial continues to track towards a topline data readout in Q3 2026.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;We have seen very strong interest in the HERO trial within the patient community, which has been driving enrollment in the United States and in our newly opened Australia sites,&#x201d; said </font><font style="color:#2d2d2d;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Tien Lee, M.D., Founder and Chief Executive Officer of Aardvark.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> &#x201c;In addition, all patients who have completed the 12-week clinical trial to date have enrolled in the Open Label Extension trial, which is an encouraging indicator of patient interest and engagement.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">US trial sites are actively enrolling, and sites in Australia started enrolling in November. Enrollment is expected to initiate shortly in Canada and the UK, where regulatory clearance has been received.  At this time, Aardvark anticipates that it will not need to activate previously planned sites in the EU to fully enroll the HERO trial and meet its anticipated timeline for topline data readout in Q3 2026.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;It&#x2019;s important to note that significant unmet needs continue to persist in the PWS community, and many families are eager for a therapy that could ameliorate the relentless hunger that is a hallmark of PWS,&#x201d; added Manasi Jaiman, M.D., Chief Medical Officer of Aardvark.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">About the HERO Trial</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The Hunger Elimination or Reduction Objective (HERO) trial (</font><font style="color:#467886;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">NCT06828861</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">) is a Phase 3 randomized, double-blind, placebo-controlled trial assessing ARD-101 for the treatment of hyperphagia in patients with Prader-Willi syndrome (PWS). Aardvark plans to enroll 90 patients in this clinical trial across the US, Australia, Canada, the United Kingdom, and South Korea. The primary endpoint is change in the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score from baseline to Week 12. Secondary outcome measures include change in Caregiver Global Impression of Severity (CaGI-S) for hyperphagia in PWS patients and change in Clinical Global Impression of Severity (CGI-S) score for hyperphagia in PWS patients. Topline data is expected in the third quarter of 2026.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">About ARD-101</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">ARD-101 is a gut-restricted small molecule agonist of select taste receptors (TAS2Rs) expressed on the luminal side of the intestine. As a potent bitter taste receptor pan-agonist, ARD-101 stimulates enteroendocrine cells of the digestive tract to release multiple gut-peptide hormones, including GLP-1 and the satiety hormone cholecystokinin (CCK), which activates gut-brain neurologic signaling to mediate hunger. ARD-101 has demonstrated an ability to reduce hunger when used alone or in combination with currently available GLP-1 therapies.  The FDA has granted ARD-101 both Orphan Drug Designation and Rare Pediatric Disease Designation for PWS.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">ARD-101 is being evaluated in the Phase 3 HERO trial for hyperphagia associated with PWS.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">About Aardvark Therapeutics, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Aardvark is a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome and metabolic diseases. Hunger, which is the discomfort from not having eaten recently, is a distinct neural signaling pathway separate from appetite, the reward-seeking desire for food. Our programs explore therapeutic applications in hunger-associated indications and potential complementary uses with anti-appetite therapies. Our lead compound, oral ARD-101, is in Phase 3 clinical development for the treatment of hyperphagia associated with PWS, a rare disease characterized by insatiable hunger. Aardvark is also developing ARD-201, a planned fixed-dose combination of ARD-101 with a DPP-4 inhibitor, through two separate Phase 2 trials with a goal of addressing some of the limitations of currently marketed GLP-1 therapies for obesity and obesity-related conditions. For more information, visit </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">aardvarktherapeutics.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Forward-Looking Statements </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"><br>Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute &#x201c;forward-looking statements.&#x201d; These statements include, but are not limited to, statements concerning:  Aardvark&#x2019;s business strategy, product candidates, ongoing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">clinical trials, planned clinical trials, expected timing for data readouts and reporting interim, preliminary or topline results, likelihood of success, as well as plans and objectives of management for future operations. The words, without limitation, &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will,&#x201d; &#x201c;would&#x201d; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words.  Forward-looking statements in this press release include statements regarding ARD-101, including the expected timeline for receiving topline data from the Phase 3 HERO trial and the intended sites for conducting and completing enrollment for the trial. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to potential delays in the commencement, enrollment and completion of clinical trials; the risk that Aardvark may use its capital resources sooner than expected and that they may be insufficient to allow Aardvark to achieve its anticipated milestones; risks related to its dependence on third parties for manufacturing, shipping and production of drug product for use in clinical trials and preclinical studies; the risk of unfavorable clinical trial results; the risk that results from earlier clinical trials and preclinical studies may not necessarily be predictive of future results; and other risks and uncertainties, including the factors described under the &#x201c;Risk Factors&#x201d; section of Aardvark&#x2019;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 that Aardvark filed with the Securities and Exchange Commission on November 13, 2025. When evaluating Aardvark&#x2019;s business and prospects, careful consideration should be given to these risks and uncertainties. Any forward-looking statements contained in this press release are based on the current expectations of Aardvark&#x2019;s management team and speak only as of the date hereof, and Aardvark specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, unless required by law.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">###</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Contact</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Carolyn Hawley, Inizio Evoke Comms</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(619) 849-5382</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Carolyn.hawley@inizioevoke.com</font></font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">    </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img213560662_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img213560662_0.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !V 2X# 2(  A$! Q$!_\0
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MKDGR\_++DO;FY7RW[<UK7\KD\\.;DYH\]K\O,N:W?EO>WG8Z6BBBI*"BBB@
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M+[PKJL%Y<Z?<1ZEX.NK"RUB",I?61:.ZN[G3X[Z&)9HYKJ:TWJTK5_03;_\
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M^".@?$KQCX4B\):SJ-]J5BUO9I=1Z5J]M8R1"'7-'BO9;BZBL+DRO:%)+J[
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MU";3]#\0:5JUU'9)HNGVQO)K>PN[B2.W$\JPK-(JH9'*(20X'W2/^".'[!8
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MFBWEO?#VC)<^*M3MT"KK7C/5R=1\4:KN.9)(9M5GGM]/\UGD@TFVT^TW%+9
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MUK3+?2K6]N(9C9V.FIHWG2K8FWN+FXNC'<2&V@2*3Z8_X)M_M&_$3]H?X/\
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M*C7Q'B'DDJ.*J8;!9=EN55YX%U(K#T7E\*-2%"E#%1KMU9U,KQA^U?\ M#_
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M7M'TRV6]35].T/4M4O(8]+U :C:-X?U+SM2O+2ZN#;:E&A6.:.TBN([D7?\
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M9T9SG5J2_$#_ ()0?LDG]IS]I72M6\2Z;]K^%OP@-CXX\;">(O9:M>P7+?\
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0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ck0001774857-20251210.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-12-10T16:45:32.9250+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://aardvarktherapeutics.com/20251210" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:ck0001774857="http://aardvarktherapeutics.com/20251210" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ck0001774857-20251210.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information, Former Legal or Registered Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10200.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName" order="10150.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 10, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 10,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Aardvark Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001774857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-42513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-1606367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4370 La Jolla Village Drive, Suite 1050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">225-7696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.00001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AARD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ck0001774857-20251210.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ck0001774857-20251210.htm">ck0001774857-20251210.htm</File>
    <File>ck0001774857-20251210.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ck0001774857-20251210.htm": {
   "nsprefix": "ck0001774857",
   "nsuri": "http://aardvarktherapeutics.com/20251210",
   "dts": {
    "inline": {
     "local": [
      "ck0001774857-20251210.htm"
     ]
    },
    "schema": {
     "local": [
      "ck0001774857-20251210.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_cca47cb1-b879-4739-a929-d7c7ef607856",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001774857-20251210.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cca47cb1-b879-4739-a929-d7c7ef607856",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001774857-20251210.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://aardvarktherapeutics.com/20251210/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001193125-25-314364-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-314364-xbrl.zip
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M\P\DC0@8V?BIGX'""+T<7H<=EEP(]"?A9]TWK3& @D(*-BY#97%2F<3IX7
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M:E#P1F+@06 +XK+S*G!9BYBA,5#-1.1S0&BA4S]@'N6>+SQ?Y]PV%K;<SD
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M'RBLC!K-ETBZ,RU)C/?C 0E9'^/F*J*9E9', D/") <PP(<T4='70'18'&$
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MB2:@?$O?DTE-#1U,@KT9)Y-^*SWA:Q)5=.U?UN\*$: 'NOLM%P:5$\TLF3K
M8^*(ZHNB!=^**2J0$TS6$MWV1($8)ILU>,9:\#Q.TL:)F9D)=<0X9SQ;#>L/
M^5_@E^]7#!9C@['K<6QZ$BF@UF\5[^OUD!I  UG!4L7!4P6I[/V:2%U!7QG
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M2^'FTY1G#_?H?WQX\MWA'O]?$?\#4$L! A0#%     @ VX:*6ZAI-(QD%
M2+8  !D              ( !     &-K,# P,3<W-#@U-RTR,#(U,3(Q,"YH
M=&U02P$"% ,4    " #;AHI;+QM=F>T(  #!90  &0              @ &;
M%   8VLP,# Q-S<T.#4W+3(P,C4Q,C$P+GAS9%!+ 0(4 Q0    ( -N&BEMI
M>BWW$!$   YC   7              "  ;\=  !C:S P,#$W-S0X-3<M97@Y
=.5\Q+FAT;5!+!08      P # -,    $+P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>ck0001774857-20251210_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ck0001774857-20251210.xsd" xlink:type="simple"/>
    <context id="C_cca47cb1-b879-4739-a929-d7c7ef607856">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001774857</identifier>
        </entity>
        <period>
            <startDate>2025-12-10</startDate>
            <endDate>2025-12-10</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_c60d0c38-5a87-4f49-b0a8-c37fa816e7d8">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_646edefe-1104-4a5c-9091-78be623abe93">0001774857</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_19ff11d6-457e-4ac9-9375-f62ab0f89ef7">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_e2f66d71-ca03-4d10-be54-be3207e2ce04">2025-12-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_b2f054e9-c53b-4ec3-9598-672877d13569">Aardvark Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_3aa45972-9a81-41e6-9e91-76fd704a1b09">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_29ba7234-a544-432e-8988-5dd677cf5249">001-42513</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_3d72b4fd-b069-4aaa-a435-e57c4096a1e1">82-1606367</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_da157c2c-0375-4f21-be55-bc549ab27060">4370 La Jolla Village Drive, Suite 1050</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_f7ed738e-0bfb-49c1-81d6-8476631ba090">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_241a2319-f124-4b25-b0e1-45f3e487fe52">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_5f1fdfb8-3292-4a86-bb6b-a021a7b60246">92122</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_da54936d-78d7-4288-b4d7-fc6aa62fd96b">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_398db6e3-33c7-4b55-b189-b8245004f9ae">225-7696</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_934325b3-3685-4609-9d8f-ebd29e122aa8">N/A</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:WrittenCommunications
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_d9261a67-4d94-46b7-900d-6c5bb042a1ad">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_0fa20ab3-ef9d-4de1-9ba8-d89e891dd52e">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_c61dd3b3-25eb-41e8-a82d-eed69c9fef31">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_02d09e01-d257-42d0-8ea7-4c304ed46c7d">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_f67bc350-f156-4c3c-a415-351e45c2d347">Common Stock, par value $0.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_49040936-7831-4e47-bc4b-d1b40ae52d87">AARD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_88e22f2b-ae80-4eba-82f6-dcf73698a15f">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_388285ae-3dfd-4e0f-a91a-f9127a32a676">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_cca47cb1-b879-4739-a929-d7c7ef607856"
      id="F_53859792-34b8-483b-833d-0210a7ac3b17">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
